<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577238</url>
  </required_header>
  <id_info>
    <org_study_id>SPL7013-015</org_study_id>
    <nct_id>NCT01577238</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Starpharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Starpharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to
      placebo gel for the treatment of bacterial vaginosis (BV).

      After screening eligible participants will be randomized to receive either 1% SPL7013 Gel or
      hydroxyethyl cellulose (HEC) placebo gel at a dose of 5g administered vaginally at bedtime
      for 7 consecutive days. Participants will be assessed for BV (both by Amsel criteria and
      Nugent score) at screening/Baseline, after last application (End of Treatment, EOT, Day 9-12)
      and at the final study visit approximately 2-3 weeks after last dose (Test of Cure, TOC, Day
      21-30).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women with Clinical Cure at the Test of Cure visit (TOC)</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Clinical Cure is defined as the resolution of clinical findings (ie Amsel criteria) from the Baseline visit (Day 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of women with Clinical Cure at the End of Treatment visit (EOT)</measure>
    <time_frame>Day 9-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with Nugent Cure at the TOC visit</measure>
    <time_frame>Day 21-30</time_frame>
    <description>Nugent Cure is defined as a score of 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with Nugent Cure at the EOT visit</measure>
    <time_frame>Day 9-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Screening - TOC</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>VivaGel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HEC Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% SPL7013 Gel</intervention_name>
    <description>Vaginal gel, daily for 7 days</description>
    <arm_group_label>VivaGel</arm_group_label>
    <other_name>VivaGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal gel, daily for 7 days</description>
    <arm_group_label>HEC Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key eligibility criteria:

          -  Post-menarchal females, aged 12 years or more

          -  Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms:
             presence of white to grey homogeneous discharge; positive whiff test indicating an
             amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5;
             and presence at least 20% clue cells of total epithelial cells

          -  Nugent score of at least 4

          -  Otherwise healthy, as determined by medical history, physical examination

          -  normal Pap smear at or documented within 24 months of screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Paull, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Starpharma Pty Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <disposition_first_submitted>October 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 25, 2012</disposition_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPL7013</keyword>
  <keyword>VivaGel</keyword>
  <keyword>bacterial vaginosis</keyword>
  <keyword>BV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

